A Rapid Immunoassay for the Simultaneous Direct Detection and Differential Diagnosis of SARS-CoV-2, Influenza Type A and Type B Antigen from anterior nasal and nasopharyngeal swab specimens.

Available in Canada

medical workers examine corona virus and carry out disinfection

Benefits of using Status™ COVID-19/Flu A&B

COVID-19 - Anterior Nasal - Sensitivity 93.8%, Specificity 100% Nasopharyngeal - Sensitivity 93.1%, Specificity 100%
Flu A - Sensitivity 91.4%, Specificity 95.7%
FDA Emergency Use Authorization (EUA)
Flu B - Sensitivity 87.6%, Specificity 95.9%
Visually read in 15 minutes
Flocked swabs for superior specimen collection and patient comfort

Training Video

Download Sell Sheet


Interested? Contact Us for More Information

Scroll to Top